


ULTRASIGHT




**AI REAL TIME
GUIDANCE PIVOTAL
STUDY RESULTS**



ULTRASIGHT'S AI REAL TIME GUIDANCE CARDIAC ULTRASOUND SOFTWARE



Real-time guidance and quality assessment for the easy capture of high-quality cardiac images by minimally trained clinical personnel




FDA Clearance, CE Mark and UKCA Mark labeling: The UltraSight AI Guidance is intended to assist medical professionals (not including expert sonographers) in acquiring cardiac ultrasound images. UltraSight AI Guidance is an accessory to compatible general-purpose diagnostic ultrasound systems. [Click here](#) for more information.

ULTRASIGHT'S LANDMARK PIVOTAL STUDY

UltraSight has successfully concluded its multicenter pivotal study at two U.S. locations, the University of Chicago and Aurora St. Luke's Medical Center in Milwaukee, Wisconsin, and at the Sheba Medical Center in Israel.

The goal of the study was to assess in a prospective study the quality of echocardiographic exams performed by inexperienced users guided by UltraSight AI Guidance software and evaluate their suitability for diagnostic interpretation of basic cardiac pathology and quantitative analysis of cardiac chamber and function.



PIVOTAL STUDY DESIGN

Healthcare Providers

6 registered nurses and 3 medical residents with no prior echocardiography experience, participated in a training program to learn cardiac point of care ultrasound (POCUS) and use of UltraSight's guidance software



Training: 2h lecture, 6h of hands-on practice and 8 practice scans

Subject Enrollment

240 subjects underwent limited echo scans performed by both novice and expert sonographers



Aurora Health Center
(81 subjects)



University of Chicago
(75 subjects)




Sheba Medical Center
(84 subjects)

Examination Evaluation

480 examinations were evaluated by 5 expert cardiologists who were blinded to the operator type


PIVOTAL STUDY RESULTS - PRIMARY ENDPOINTS

NUMBER OF EXAMS WITH SUFFICIENT DIAGNOSTIC QUALITY TO EVALUATE SPECIFIED CLINICAL DATA



PIVOTAL STUDY RESULTS - SECONDARY ENDPOINTS

NUMBER OF EXAMS WITH SUFFICIENT DIAGNOSTIC QUALITY TO EVALUATE SPECIFIED CLINICAL DATA



EXAM QUALITY AND DIAGNOSIS AGREEMENT BETWEEN NOVICE VS SONOGRAPHERS

Percentages of exams with sufficient quality to allow diagnostic interpretation (center) and percentages of exams resulting in concordant diagnostic interpretation from images acquired by sonographers and by novices (right)

	% Diagnostic quality (CI)		% Diagnostic agreement
	Sonographers	Novices	
LV size	100% (98-100)	99% (99-100)	96% (92-98)
LV function	100% (98-100)	100% (97-100)	86% (81-90)
RV size	98% (96-99)	93% (89-99)	87% (82-91)
Pericardial effusion	100% (98-100)	100% (98-100)	94% (90-96)
RV function	98% (97-100)	94% (90-98)	96% (93-98)
LA size	99% (98-100)	94% (90-97)	83% (77-87)
AV structure	97% (97-100)	89% (84-93)	88% (82-91)
MV structure	98% (97-100)	98% (95-99)	90% (96-93)
TV structure	89% (86-99)	74% (67-80)	95% (90-97)
IVC size	87% (82-90)	67% (59-75)	85% (78-90)



ADDITIONAL ANALYSIS – NOVICE VS SONOGRAPHER CORRELATION

LV FUNCTION, VOLUME AND STRAIN*

	Sonographers	Novices	Delta	R-value (p)
LVEF (%)	58 (52 – 64)	58 (52 – 63)	-0.2 ± 8.2	0.78 (<0.001)
LVEDV (ml)	102 (75 – 126)	97 (70 – 135)	-4 ± 30	0.78 (<0.001)
LVESV (ml)	42 (27 – 57)	41 (25 – 64)	-2 ± 22	0.82 (<0.001)
GLS (%)	-18 (-21 – -15)	-17 (-19 – -14)	1.2 ± 3.3	0.74 (<0.001)

LVEF – Left Ventricle Ejection Fraction; LVEDV – Left Ventricle End Diastolic Volume; LVESV – Left Ventricle End Systolic Volume; GLS – Global Longitudinal Strain

*Subset follow-up analysis on 100 participants



PIVOTAL STUDY RESULTS



The results demonstrated that after minimal training with the novel real-time guidance software, novice users can acquire images of diagnostic quality approaching that of expert sonographers in the majority of patients, allowing qualitative diagnostic interpretation and quantitative analysis.





CE MARK

Achieved in
August 2022



UKCA

Achieved in
December 2022



FDA 510(K) CLEARED

Achieved in
July 2023



ISRAELI AMAR

Achieved in
September 2023

FOR MORE INFORMATION ABOUT ULTRASIGHT'S CARDIAC
ULTRASOUND GUIDANCE SOLUTION, VISIT OUR [WEBSITE](#).

ULTRASIGHT



**THANK
YOU.**

